This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	IL-20	<p>Studies in mice and in human samples suggest inhibiting IL-20 could help treat breast cancer and breast cancer-induced bone loss. In primary breast tumor samples, levels of IL-20 were inversely correlated with metastasis-free survival. In mice with mammary tumors, an anti-IL-20 antibody lowered tumor growth compared with control IgG. In mouse models of metastatic mammary cancer, the antibody decreased both the number of bone metastases and bone loss compared with control IgG. Ongoing work includes testing IL-20 inhibition in animal models of bone metastases of prostate and other cancers.</p> <p>NN8226 (anti-IL20), an anti-IL-20 mAb from Novo Nordisk A/S, is in Phase II testing to treat rheumatoid arthritis (RA).</p> <p>SciBX 5(5); doi:10.1038/scibx.2012.119 Published online Feb. 2, 2012</p>	Patented by National Cheng Kung University; available for licensing	<p>Hsu, Y.-H. <i>et al. J. Immunol.</i>; published online Jan. 11, 2012; doi:10.4049/jimmunol.1102843</p> <p>Contact: Ming-Shi Chang, National Cheng Kung University, Tainan, Taiwan e-mail: mschang@mail.ncku.edu.tw</p>